.jpg)
GAL(1-15) and analogues thereof for use in the prevention and/or treatment of alcohol-related effects and disorders
Alcohol is one of the most consumed drugs globally, being responsible for a large number of health-related problems. Despite the great socioeconomic impact that alcohol consumption entails, there is a lack of effective treatments for its addiction. Recently, neuropeptides are beginning to be considered as key players in some neuropsychiatric diseases, including alcoholism, and therefore, key targets for finding new treatments. In recent studies in animal models, the use of Galanine fragment (1-15) is proposed as a therapy capable of producing a decrease in voluntary alcohol consumption as well as a great decrease in the preference for this substance. Specifically, the present invention proposes the use of Galanine (1-15) to rapidly decrease alcohol preference and consumption in people with alcohol abuse.
Pharmaceutical sector. Applications in the treatment of addiction to alcohol and other drugs of abuse. Currently, there are only three drugs approved for the treatment of alcoholism, but none of them are certainly effective. The appearance of a new drug capable of reducing alcohol preference and consumption quickly, as demonstrated in pre-clinical studies, would be a great advantage for the treatment of alcoholism and its associated pathologies. Since the effect of Galanine (1-15) on alcoholism seems to be related to a depletion of the natural reinforcement system, its use would not only help to reduce the consumption of alcohol but also of other substances of abuse that are consumed together with it.
